ArticleFrontiers in pediatrics2026
Case Report: Primary bile acid synthesis defect: first cases series from Tunisia.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary bile acid synthesis defects (BASD) are autosomal recessive disorders causing cholestatic liver disease and fat-soluble vitamin malabsorption. Despite being treatable with cholic acid (CA), BASD remain underdiagnosed, particularly in resource-limited settings. No data have been published from Tunisia. Methods: A retrospective study of all patients diagnosed with BASD at La Rabta University Hospital in Tunis, between 2013 and 2024 described clinical presentation, biochemical and genetic findings, treatment and outcomes. Results: Six male patients from three unrelated families were enrolled. The age at symptom onset ranged from the neonatal period to 8 years, with a diagnostic delay spanning from 1.5 months to 5 years. Three distinct phenotypes were observed: cholestasis (3/6), malabsorption (4/6), and non-cholestatic hepatopathy (1/6). Four patients presented with 3β-hydroxysteroid dehydrogenase deficiency, including three siblings homozygous for a novel Conclusions: This first Tunisian small series highlights the phenotypic heterogeneity of BASD, even in the same family, and the efficacy of CA therapy when initiated early. Besides low GGT cholestasis, fat-soluble vitamin malabsorption and non-cholestatic liver phenotype require investigation of serum bile acids as well as bile acids in urine. Improved access to specialized diagnostic tools and orphan drug therapies is urgently needed in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.